PMID- 33709186
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20211015
IS  - 1433-7339 (Electronic)
IS  - 0941-4355 (Linking)
VI  - 29
IP  - 9
DP  - 2021 Sep
TI  - Poorer baseline performance status is associated with increased thromboembolism 
      risk in metastatic cancer patients treated with immunotherapy.
PG  - 5417-5423
LID - 10.1007/s00520-021-06139-3 [doi]
AB  - PURPOSE: Venous thromboembolism (VTE) is a significant cause of morbidity and 
      mortality in cancer patients. However, the association of VTE with immunotherapy 
      remains poorly defined. We therefore evaluated the frequency of VTE in patients 
      receiving immunotherapy and tried to determine predisposing factors. METHODS: A 
      total of 133 adult metastatic cancer patients treated with immunotherapy for any 
      cancer between were included. Baseline demographics, ECOG performance status, 
      type of tumors, and baseline blood count parameters were recorded. Possible 
      predisposing factors were evaluated with univariate and multivariate analyses. 
      RESULTS: The median age was 60 (interquartile range (IQR) 48-66) years, and the 
      median follow-up was 10.1 (IQR 5.8-18.5) months. Renal cell carcinoma (26.3%) and 
      melanoma (24.1%) were most common diagnoses. Fifteen patients (11.3%) had an 
      episode of VTE. Most of the VTEs were diagnosed as pulmonary emboli (10/15; 67%). 
      Eighty percent (12/15) of these VTE cases were detected incidentally. Patients 
      with a baseline ECOG performance status of 1 or more (29.3% of patients) had a 
      significantly increased risk of venous thrombosis (ECOG >/=1 vs. 0, HR: 3.023, 95% 
      CI: 1.011-9.039, p=0.048). Other factors, including patient age, tumor type, body 
      mass index, baseline thrombocyte, neutrophil, and lactate dehydrogenase levels 
      were not significantly associated with VTE risk. CONCLUSIONS: In this study, we 
      observed VTE development in more than 10% of immunotherapy-treated patients and 
      increased VTE risk in patients with poorer ECOG status. With the asymptomatic 
      nature of VTEs in most cases, a high index of suspicion level for VTE is required 
      in patients treated with immunotherapy.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Guven, Deniz Can
AU  - Guven DC
AUID- ORCID: 0000-0002-6924-9467
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey. denizcguven@hotmail.com.
FAU - Aksun, Melek Seren
AU  - Aksun MS
AD  - Department of Internal Medicine, Hacettepe University Faculty of Medicine, 
      Ankara, Turkey.
FAU - Sahin, Taha Koray
AU  - Sahin TK
AD  - Department of Internal Medicine, Hacettepe University Faculty of Medicine, 
      Ankara, Turkey.
FAU - Aktepe, Oktay Halit
AU  - Aktepe OH
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Yildirim, Hasan Cagri
AU  - Yildirim HC
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Taban, Hakan
AU  - Taban H
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Ceylan, Furkan
AU  - Ceylan F
AD  - Department of Internal Medicine, Hacettepe University Faculty of Medicine, 
      Ankara, Turkey.
FAU - Kertmen, Neyran
AU  - Kertmen N
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Arik, Zafer
AU  - Arik Z
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Dizdar, Omer
AU  - Dizdar O
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Kilickap, Saadettin
AU  - Kilickap S
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Aksoy, Sercan
AU  - Aksoy S
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Yalcin, Suayib
AU  - Yalcin S
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
FAU - Erman, Mustafa
AU  - Erman M
AD  - Department of Medical Oncology, Hacettepe University Cancer Institute, 06100 
      Sihhiye, Ankara, Turkey.
LA  - eng
PT  - Journal Article
DEP - 20210311
PL  - Germany
TA  - Support Care Cancer
JT  - Supportive care in cancer : official journal of the Multinational Association of 
      Supportive Care in Cancer
JID - 9302957
SB  - IM
MH  - Child, Preschool
MH  - Humans
MH  - Immunotherapy/adverse effects
MH  - Incidence
MH  - *Neoplasms/therapy
MH  - Risk Factors
MH  - *Venous Thromboembolism/epidemiology/etiology
OTO - NOTNLM
OT  - ECOG performance status
OT  - Immunotherapy
OT  - Venous thromboembolism
EDAT- 2021/03/13 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/03/12 07:27
PHST- 2021/01/01 00:00 [received]
PHST- 2021/03/04 00:00 [accepted]
PHST- 2021/03/13 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/03/12 07:27 [entrez]
AID - 10.1007/s00520-021-06139-3 [pii]
AID - 10.1007/s00520-021-06139-3 [doi]
PST - ppublish
SO  - Support Care Cancer. 2021 Sep;29(9):5417-5423. doi: 10.1007/s00520-021-06139-3. 
      Epub 2021 Mar 11.